Physician profile
William Scott Athans
NPI 1417902156
$3,498.92
in general payments reported to CMS, 2019-2025
17 companies · $645 in 2025
The $645 reported for 2025 was more than what 83% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $798 · 2020: $126 · 2021: $93.46 · 2022: $1,196 · 2023: $498 · 2024: $143 · 2025: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,286.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $1,667.21 | 2019-2024 | Myday Contact Lens |
| Alcon Vision LLC | $852.02 | 2019-2025 | Clareon, Precision7, Dailies Total1 |
| Bausch & Lomb Americas INC. | $274.38 | 2022-2025 | Infuse, Vyzulta, Xiidra |
| Biotissue Holdings INC. | $131.67 | 2022 | |
| Allergan, INC. | $84.19 | 2019-2022 | |
| Johnson & Johnson Vision Care, INC. | $78.34 | 2021-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $77.33 | 2020 | |
| Apellis Pharmaceuticals, INC. | $66.04 | 2025 | Syfovre |
| Aerie Pharmaceuticals, INC. | $50.06 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $40.05 | 2022-2023 | |
| Notal Vision, INC. | $35.52 | 2024 | Foresee Home |
| Horizon Therapeutics Plc | $33.86 | 2023 | Tepezza |
| Harrow Eye, LLC | $27.90 | 2025 | Vevye |
| Oyster Point Pharma, INC. | $26.63 | 2023 | Tyrvaya |
| Thea Pharma INC. | $22.07 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $16.48 | 2025 | |
| Tarsus Pharmaceuticals, INC. | $15.17 | 2024 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Athans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.